Pharmacodynamic Models for Discrete DataPAULE, Ines; GIRARD, Pascal; FREYER, Gilles et al.Clinical pharmacokinetics. 2012, Vol 51, Num 12, pp 767-786, issn 0312-5963, 20 p.Article

Pharmacodynamic Effects in the Cardiovascular System: The Modeller's ViewFINK, Martin; NOBLE, Denis.Basic & clinical pharmacology & toxicology (Print). 2010, Vol 106, Num 3, pp 243-249, issn 1742-7835, 7 p.Conference Paper

Pharmacodynamic Effects of Haematopoietic Cytokines: The View of a Clinical OncologistHELD, Thomas K; GUNDERT-REMY, Ursula.Basic & clinical pharmacology & toxicology (Print). 2010, Vol 106, Num 3, pp 210-214, issn 1742-7835, 5 p.Conference Paper

Reporting a Population Pharmacokinetic-Pharmacodynamic Study: A Journal's PerspectiveJAMSEN, Kris M; McLEAY, Sarah C; BARRAS, Michael A et al.Clinical pharmacokinetics. 2014, Vol 53, Num 2, pp 111-122, issn 0312-5963, 12 p.Article

Pharmacokinetic and pharmacodynamic properties important for inhaled corticosteroidsHOCHHAUS, Gunther.Annals of allergy, asthma, & immunology. 2007, Vol 98, Num 2, issn 1081-1206, S7-S15, SUP2Article

In Vivo Pharmacodynamics of New Lipopeptide MX-2401CRAIG, W. A; ANDES, D. R; STAMSTAD, T et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 12, pp 5092-5098, issn 0066-4804, 7 p.Article

Disease Severity Is a Major Determinant for the Pharmacodynamics of Propofol in Critically III PatientsPEETERS, M. Y. M; BRAS, L. J; DEJONGH, J et al.Clinical pharmacology and therapeutics. 2008, Vol 83, Num 3, pp 443-451, issn 0009-9236, 9 p.Article

Pharmacodynamics and Pharmacokinetics of the Novel Thrombopoietin Mimetic Peptide RWJ-800088 in HumansLIEM-MOOLENAAR, M; CERNEUS, D; MOLLOY, C. J et al.Clinical pharmacology and therapeutics. 2008, Vol 84, Num 4, pp 481-487, issn 0009-9236, 7 p.Article

Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administrationKELLER, Alexandra; ZIDA WU; KRATZSCH, Juergen et al.European journal of endocrinology. 2007, Vol 156, Num 6, pp 647-653, issn 0804-4643, 7 p.Article

Pharmacodynamic Markers of Perifosine EfficacyHENNESSY, Bryan T; YILING LU; HENDERSON, I. Craig et al.Clinical cancer research. 2007, Vol 13, Num 24, pp 7421-7431, issn 1078-0432, 11 p.Article

AntibioticsOrtega Morente, Elena; Espinosa Ubeda, Antonio.2005, isbn 81-7736-291-7, 1Vol, 232 p., isbn 81-7736-291-7Book

Pharmacodynamic Variability beyond That Explained by MICsSOON, Rachel L; LY, Neang S; GAURI RAO et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 4, pp 1730-1735, issn 0066-4804, 6 p.Article

PhRMA Survey of Pharmacogenomic and Pharmacodynamic Evaluations: What Next?GRECCO, N; COHEN, N; FRANC, M. A et al.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 6, pp 1035-1043, issn 0009-9236, 9 p.Article

Differentiating Low-Molecular-Weight Heparins Based on Chemical, Biological, and Pharmacologic Properties : Implications for the Development of Generic Versions of Low-Molecular-Weight HeparinsJESKE, Walter P; WALENGA, Jeanine M; HOPPENSTEADT, Debra A et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, Num 1, pp 74-85, issn 0094-6176, 12 p.Article

Tissue concentrations : do we ever learn?MOUTON, Johan W; THEURETZBACHER, Ursula; CRAIG, William A et al.Journal of antimicrobial chemotherapy (Print). 2008, Vol 61, Num 2, pp 235-237, issn 0305-7453, 3 p.Article

Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjectsPICCOLI, Franziska; DEGEN, Lukas; MACLEAN, Carol et al.The Journal of clinical endocrinology and metabolism. 2007, Vol 92, Num 5, pp 1814-1820, issn 0021-972X, 7 p.Article

The relationship between quinolone exposures and resistance amplification is characterized by an inverted U : a new paradigm for optimizing pharmacodynamics to counterselect resistanceTAM, Vincent H; LOUIE, Arnold; DEZIEL, Mark R et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 2, pp 744-747, issn 0066-4804, 4 p.Article

Pharmacodynamics of Razupenem (PZ601) Studied in an In Vitro Pharmacokinetic Model of InfectionMACGOWAN, Alasdair P; NOEL, Alan; TOMASELLI, Sharon et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 4, pp 1436-1442, issn 0066-4804, 7 p.Article

Interactions médicamenteuses: très souvent d'ordre pharmacodynamique : Les faits marquantsLa Revue Prescrire. 2014, Vol 34, Num 373, issn 0247-7750, p. 836Conference Paper

Histone yH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic BiomarkersREDON, Christophe E; NAKAMURA, Asako J; ZHANG, Yong-Wei et al.Clinical cancer research (Print). 2010, Vol 16, Num 18, pp 4532-4542, issn 1078-0432, 11 p.Article

In vivo pharmacodynamic activity of the glycopeptide dalbavancinANDES, David; CRAIG, William A.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 5, pp 1633-1642, issn 0066-4804, 10 p.Article

Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humansSCHMIDT, Helmut; LÖTSCH, Jörn.European journal of clinical pharmacology. 2007, Vol 63, Num 11, pp 1045-1054, issn 0031-6970, 10 p.Article

The hollow fibre model -facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfareSUGGITT, Marie; COOPER, Patricia A; SHNYDER, Steven D et al.International journal of oncology. 2006, Vol 29, Num 6, pp 1493-1499, issn 1019-6439, 7 p.Article

Pharmacodynamics of antibioticsGALISTEO, M; DUARTE, J; ZARZUELO, A et al.2005, pp 1-18, isbn 81-7736-291-7, 1Vol, 18 p.Article

Pharmacodynamics Modeling To Optimize Dosage Regimens of SulbactamJARURATANASIRIKUL, Sutep; WONGPOOWARAK, Wibul; AEINLANG, Nanchanit et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 7, pp 3441-3444, issn 0066-4804, 4 p.Article